CheckMate 214 Results Positive Overall
Dr. Scott S. Tykodi, MD reveals the results of the Checkmate - 214 trial with combined immunotherapy nivolumab plus ipilimumab and explains the positive results on objective response rate and prolonge...
Author: Cancer-News
Added: 09/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 18, 2017 Category: Cancer & Oncology Source Type: podcasts
Nivolumab versus Nivolumab Combined with Ipilimumab in Patients with Melanoma Brain Metastases
Daniela Bota, MD of UC Irvine Health discusses the results of nivolumab versus nivolumab plus ipilimumab in patients with Melanoma at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach,...
Author: moasc
Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-029 Results: Pembrolizumab + Low-Dose Ipilimumab in Metastatic Melanoma Patients
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL. <br /><br />Pembro...
Author: ASCO2017
Added: 06/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Impact of Combination of Talimogene and Ipilimumab on Clinical Practice
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Common Questions Asked Concerning the Study
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: Phase II Study of Talimogene Laherparepvec and Ipilimumab in Melanoma
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in m...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Drug Combination, Ipilimumab and Nivolumab, in Advanced Melanoma
Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the use of ipilimumab and nivolumab in advanced melanoma. This was recorded at the American Association for Cancer ...
Author: aacr2017
Added: 04/28/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 28, 2017 Category: Cancer & Oncology Source Type: podcasts
Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study @KidneyCancer
Hans J. Hammers, MD of the University of Texas Southwestern Medical Center discusses Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma...
Author: kidneycancer
Added: 04/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 25, 2017 Category: Cancer & Oncology Source Type: podcasts
More Confidence to Try Nivolumab and Ipilimumab Combo in Previously Treated Patients
Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma, especially since there is a 20% response r...
Author: ASCO-SITC2017
Added: 03/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2017 Category: Cancer & Oncology Source Type: podcasts
21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab
Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Author: ASCO-SITC2017
Added: 03/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2017 Category: Cancer & Oncology Source Type: podcasts
More Combinations like Nivolumab and Ipilimumab Coming for Lung, Bladder, and Kidney Cancer
Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab. This combination therapy is FDA approved for Melanoma, but...
Author: ASCO-SITC2017
Added: 03/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2017 Category: Cancer & Oncology Source Type: podcasts
Benefits and risks of treatment with ipilimumab after complete resection of Stage III melanoma
Dirk Schadendorf, MD, PhD, from the University Hospital Essen, Essen, Germany, discusses the risks and benefits of adjuvant ipilimumab treatment after complete resection of Stage III melanoma based on...
Author: VJOncology
Added: 02/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2017 Category: Cancer & Oncology Source Type: podcasts
Two Ipilimumab Trials Show Survival Benefit, and More Toxicity
Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity. (Source: Medscape Oncology)
Source: Medscape Oncology - October 31, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Big News: Adjuvant Ipi Improves Survival in Melanoma
Dr Caroline Robert reviews melanoma highlights from ESMO 2016, focusing on results of ipilimumab in the adjuvant setting and the highest 3-year survival achieved in metastatic disease. (Source: Medscape Oncology)
Source: Medscape Oncology - October 17, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
